文献速递眼底病与葡萄膜炎

比较年龄相关性黄斑变性治疗试验5年随访中地图样萎缩的发生率与生长

Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.
PubMed 文献 · Ophthalmology · 2016-10-27

在CATT试验中,基线无地图样萎缩(GA)且随访图像可评估的1011例参与者,GA累积发生率1年12%、2年17%、5年38%;总体GA生长速率为0.33 mm/年(SE 0.02),前2年接受雷珠单抗治疗眼较贝伐珠单抗治疗眼生长速率更高(校正生长速率0.38 vs 0.28 mm/年;P=0.009)。

要点

  • 基线无GA的CATT参与者5年GA累积发生率为38%。
  • 总体GA生长速率为0.33 mm/年(SE 0.02)。
  • 前2年雷珠单抗治疗眼GA生长速率高于贝伐珠单抗眼(0.38 vs 0.28 mm/年;P=0.009)。

核心结论

  • 开始治疗5年后GA发生常见,2年随访时识别的多项危险因素在5年随访时持续存在。

研究设计与样本

  • CATT临床试验内队列,共1185例参与者随机分配至雷珠单抗或贝伐珠单抗及3种治疗方案,2年时停止方案治疗,约5年时检查(N=647)。
  • 两名设盲分级者对基线和第1、2、5年数字彩色照片和荧光素血管造影评估GA存在与大小。

主要发现

  • 基线无GA且随访图像可分级者1011例中,GA累积发生率1年12%、2年17%、5年38%。
  • 总体GA生长速率为0.33 mm/年(SE 0.02 mm/年)。
  • 前2年雷珠单抗治疗眼GA生长速率高于贝伐珠单抗治疗眼(校正生长速率0.38 vs 0.28 mm/年;P=0.009)。
  • 基线年龄较大、高胆固醇血症、视力较差、脉络膜新生血管面积较大、视网膜血管瘤样增生病灶、对侧眼GA及视网膜内液与GA发生风险较高相关。
  • 较厚的视网膜下组织复合体及视网膜下液存在与GA发生较少相关;对侧眼GA、出血及基线无视网膜色素上皮下液与GA生长速率较高相关。

关键数值与推荐

  • GA累积发生率:1年12%、2年17%、5年38%(基线无GA且随访图像可分级者1011例)。
  • 总体GA生长速率0.33 mm/年(SE 0.02 mm/年)。
  • 前2年雷珠单抗治疗眼校正GA生长速率0.38 mm/年 vs 贝伐珠单抗治疗眼0.28 mm/年(P=0.009)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To estimate the incidence, size, and growth rate of geographic atrophy (GA) during 5 years of follow-up among participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). DESIGN: Cohort within a clinical trial. PARTICIPANTS: Participants included in CATT. METHODS: A total of 1185 CATT participants were randomly assigned to ranibizumab or bevacizumab treatment and to 3 treatment regimens. Participants were released from protocol treatment at 2 years and examined at approximately 5 years (N = 647). Two masked graders assessed the presence and size of GA in digital color photographs (CPs) and fluorescein angiograms (FAs) taken at baseline and years 1, 2, and 5. Cox proportional hazard models were used to identify risk factors for incidence of GA. Annual change in the square root of the total area of GA was the measure of growth. Multivariate linear mixed models including baseline demographic, treatment, and ocular characteristics on CP/FA and optical coherence tomography (OCT) as candidate risk factors were used to estimate adjusted growth rates, standard errors (SEs), and 95% confidence intervals (CIs). MAIN OUTCOME MEASURES: Geographic atrophy incidence and growth rate. RESULTS: Among the 1011 participants who did not have GA at baseline and had follow-up images gradable for GA, the cumulative incidence was 12% at 1 year, 17% at 2 years, and 38% at 5 years. At baseline, older age, hypercholesterolemia, worse visual acuity, larger choroidal neovascularization (CNV) area, retinal angiomatous proliferation (RAP) lesion, GA in the fellow eye, and intraretinal fluid were associated with a higher risk of incident GA. Thicker subretinal tissue complex and presence of subretinal fluid were associated with less GA development. The overall GA growth rate was 0.33 mm/year (SE, 0.02 mm/year). Eyes treated with ranibizumab in the first 2 years of the clinical trial had a higher growth rate than eyes treated with bevacizumab (adjusted growth rate, 0.38 vs. 0.28 mm/year; P = 0.009). Geographic atrophy in the fellow eye, hemorrhage, and absence of sub-retinal pigment epithelium fluid at baseline were associated with a higher growth rate. CONCLUSIONS: Development of GA is common 5 years after initiating therapy. Several risk factors identified at 2 years of follow-up persist at 5 years of follow-up.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Grunwald JE, Pistilli M, Daniel E, et al. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016. PMID: 28079023. doi:10.1016/j.ophtha.2016.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。